The preplanned safety analysis was done after eight patients had been treated , because of haematological adverse events ( three patients had grade @ thrombocytopenia and two had grade @ thrombocytopenia ) which reduced bevacizumab dose intensity ; the lomustine dose in the combination treatment group was thereafter reduced to @ mg/m ( @ ) .